

**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**  
 (Currently amended claims showing deletions by ~~strike through~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

1-7. (Canceled)

8. (Currently amended)      A compound ~~according to claim 6~~, wherein said compound is  
 according to the formula:

$((2,3,4,5,6\text{-F})\text{Phe}^{20})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 31)
$((2,3,4,5,6\text{-F})\text{Phe}^{21})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 32)
$\text{Ac}-((2,3,4,5,6\text{-F})\text{Phe}^{26})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 33)
$\text{Ac}-((2,3,4,5,6\text{-F})\text{Phe}^{26})\text{hPYY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 34)
$((2,3,4,5,6\text{-F})\text{Phe}^{26})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 35)
$\text{Ac}-((2,3,4,5,6\text{-F})\text{Phe}^{27})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 36)
$\text{Ac}-((2,3,4,5,6\text{-F})\text{Phe}^{27})\text{hPYY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 37)
$((2,3,4,5,6\text{-F})\text{Phe}^{27})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 38)
$\text{Ac}-((2,3,4,5,6\text{-F})\text{Phe}^{36})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 39)
$\text{Ac}-((2,3,4,5,6\text{-F})\text{Phe}^{36})\text{hPYY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 40)
$((2,3,4,5,6\text{-F})\text{Phe}^{36})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 41)
$((3,4,5\text{-F})\text{Phe}^{20})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 42)
$((3,4,5\text{-F})\text{Phe}^{21})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 43)
$\text{Ac}-((3,4,5\text{-F})\text{Phe}^{26})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 44)
$\text{Ac}-((3,4,5\text{-F})\text{Phe}^{26})\text{hPYY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 45)
$((3,4,5\text{-F})\text{Phe}^{26})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 46)
$\text{Ac}-((3,4,5\text{-F})\text{Phe}^{27})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 15)
$\text{Ac}-((3,4,5\text{-F})\text{Phe}^{27})\text{hPYY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 47)
$((3,4,5\text{-F})\text{Phe}^{27})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 12)
$\text{Ac}-((3,4,5\text{-F})\text{Phe}^{36})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 48)
$\text{Ac}-((3,4,5\text{-F})\text{Phe}^{36})\text{hPYY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 49)
$((3,4,5\text{-F})\text{Phe}^{36})\text{hPYY}(3\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 50)
$\text{Ac}-(\text{D2Pal}^{26})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 26)
$\text{Ac}-(2\text{Pal}^{26})\text{hPYY}(22\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 27)
$\text{Ac}-(2\text{Pal}^{26}, \text{Leu}^{31})\text{hPPY}(24\text{-}36)\text{NH}_2$ ;	(SEQ ID NO. 18)

---

Ac-(3Pal <sup>26</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 14)
(3Pal <sup>26</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 5)
Ac-(3Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 16)
Ac-(4Pal <sup>26</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 13)
Ac-(4Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 17)
Ac-(A5c <sup>22</sup> )hPYY(22-36)NH <sub>2</sub>	(SEQ ID NO. 4)
Ac-(A5c <sup>31</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 24)
Ac-(A5c <sup>31</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 51)
(A5c <sup>31</sup> )hPYY(3-36)NH <sub>2</sub>	(SEQ ID NO. 3)
(A6c <sup>10</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 52)
(A6c <sup>11</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 53)
(A6c <sup>12</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 54)
(A6c <sup>13</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 55)
(A6c <sup>15</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 56)
(A6c <sup>16</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 57)
(A6c <sup>17</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 58)
(A6c <sup>18</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 59)
(A6c <sup>20</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 60)
(A6c <sup>21</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 61)
Ac-(A6c <sup>22</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 62)
(A6c <sup>22</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 63)
Ac-(A6c <sup>24</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 25)
Ac-(A6c <sup>24</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 64)
(A6C <sup>24</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 10)
Ac-(A6c <sup>24</sup> , Leu <sup>31</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 28)
Ac-(A6c <sup>27</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 65)
Ac-(A6c <sup>27</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 66)
(A6c <sup>27</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 67)
Ac-(A6c <sup>28</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 23)
Ac-(A6c <sup>28</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 68)
(A6c <sup>28</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 8)
Ac-(A6c <sup>28</sup> , Leu <sup>31</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 29)
Ac-(A6c <sup>29</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 69)
Ac-(A6c <sup>29</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 70)

---

(A6c <sup>29</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 71)
(A6c <sup>3</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 72)
Ac-(A6c <sup>30</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 22)
Ac-(A6c <sup>30</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 73)
(A6c <sup>30</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 9)
Ac-(A6c <sup>31</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 21)
Ac-(A6c <sup>31</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 30)
(A6c <sup>31</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 74)
Ac-(A6c <sup>32</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 75)
Ac-(A6c <sup>32</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 76)
(A6c <sup>32</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 77)
(A6c <sup>6</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 78)
(A6c <sup>7</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 79)
(A6c <sup>9</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 80)
(Act <sup>12</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 81)
(Act <sup>13</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 82)
Ac-(Act <sup>23</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 83)
(Act <sup>23</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 84)
Ac-(Act <sup>32</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 85)
Ac-(Act <sup>32</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 86)
(Act <sup>32</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 87)
(Act <sup>7</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 88)
Ac-(Aib <sup>22</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 89)
(Aib <sup>22</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 11)
(Apc <sup>19</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 90)
Ac-(Apc <sup>25</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 91)
Ac-(Apc <sup>25</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 92)
(Apc <sup>25</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 93)
Ac-(Apc <sup>26</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 94)
Ac-(Apc <sup>26</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 95)
(Apc <sup>26</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 96)
Ac-(Apc <sup>33</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 97)
Ac-(Apc <sup>33</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 98)
(Apc <sup>33</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 99)

---

Ac-(Apc <sup>34</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 100)
Ac-(Apc <sup>34</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 101)
(Apc <sup>34</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 102)
Ac-(Apc <sup>35</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 103)
Ac-(Apc <sup>35</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 104)
(Apc <sup>35</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 7)
Ac-(Apc <sup>36</sup> )hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 105)
Ac-(Apc <sup>36</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 106)
(Apc <sup>36</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 107)
(Apc <sup>4</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 108)
(Taz <sup>26</sup> )hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 6)
Ac-(Taz <sup>26</sup> )hPYY(22-36)NH <sub>2</sub> ; <u>or</u>	(SEQ ID NO. 20)
Ac-(Taz <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 19)

or a pharmaceutically acceptable salt thereof.

9. (Currently amended) A compound according to claim 8, wherein said compound is according to the formula:

[A5C <sup>31</sup> ]hPYY(3-36)NH <sub>2</sub>	(SEQ ID NO. 3)
Ac-[A5C <sup>22</sup> ]hPYY(22-36)NH <sub>2</sub>	(SEQ ID NO. 4)
[3Pal <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 5)
[Taz <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 6)
[Apc <sup>35</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 7)
[A6C <sup>28</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 8)
[A6C <sup>30</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 9)
[A6C <sup>24</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 10)
[Aib <sup>22</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 11)
[((3,4,5-F)Phe) <sup>27</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 12)
Ac-[4Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 13)
Ac-[3Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 14)
Ac-[((3,4,5-F)Phe) <sup>27</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 15)
Ac-(3Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 16)
Ac-(4Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 17)
Ac-(2Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 18)
Ac-(Taz <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 19)

Ac-[Taz <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 20)
Ac-[A6c <sup>31</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 21)
Ac-[A6c <sup>30</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 22)
Ac-[A6c <sup>28</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 23)
Ac-[A5c <sup>31</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 24)
Ac-[A6C <sup>24</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 25)
Ac-[D2Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 26)
Ac-[2Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 27)
Ac-[A6C <sup>24</sup> , Leu <sup>31</sup> ]hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 28)
Ac-[A6C <sup>28</sup> , Leu <sup>31</sup> ]hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 29)
Ac-[A6C <sup>31</sup> ]hPYY(24-36)NH <sub>2</sub> ; <u>or</u>	(SEQ ID NO. 30)
Ac-(A6c <sup>24</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 64)

or a pharmaceutically acceptable salt thereof.

10. (Currently amended) A compound according to claim 9, wherein said compound is:

[A5C <sup>31</sup> ]hPYY(3-36)NH <sub>2</sub>	(SEQ ID NO. 3)
[3Pal <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 5)
[Taz <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 6)
[A6C <sup>28</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 8)
[A6C <sup>24</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 10)
[Aib <sup>22</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 11)
[((3,4,5-F)Phe) <sup>27</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 12)
Ac-[4Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 13)
Ac-[3Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 14)
Ac-(3Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ; <u>or</u>	(SEQ ID NO. 16)
Ac-(4Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

11. (Currently amended) A compound according to claim 9, wherein said compound is:

[A5C <sup>31</sup> ]hPYY(3-36)NH <sub>2</sub>	(SEQ ID NO. 3)
[3Pal <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 5)
[Taz <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 6)
[Apc <sup>35</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 7)
[A6C <sup>28</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 8)

[A6C <sup>24</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 10)
[Aib <sup>22</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 11)
Ac-[4Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 13)
Ac-[3Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ;	(SEQ ID NO. 14)
Ac-(3Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ; <u>or</u>	(SEQ ID NO. 16)
Ac-(4Pal <sup>26</sup> , Leu <sup>31</sup> )hPPY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

12. (Currently amended) A compound according to claim 9, wherein said compound is:

[A5C <sup>31</sup> ]hPYY(3-36)NH <sub>2</sub>	(SEQ ID NO. 3)
[3Pal <sup>26</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 5)
[A6C <sup>28</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 8)
[A6C <sup>24</sup> ]hPYY(3-36)NH <sub>2</sub> ;	(SEQ ID NO. 10)
Ac-[4Pal <sup>26</sup> ]hPYY(22-36)NH <sub>2</sub> ; <u>or</u>	(SEQ ID NO. 13)
Ac-(A6c <sup>24</sup> )hPYY(24-36)NH <sub>2</sub> ;	(SEQ ID NO. 64)

or a pharmaceutically acceptable salt thereof.

13. (Currently amended) A pharmaceutical composition comprising a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. (Withdrawn – currently amended) A method of decreasing excess intestinal water and electrolyte secretion in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof.

15. (Withdrawn – currently amended) A method of regulating cell proliferation in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof.

16. (Withdrawn) A method of claim 15, wherein said cell is a gastrointestinal cell.

17. (Withdrawn) A method of claim 15, wherein said cell is an epithelial cell.

18. (Withdrawn – currently amended) A method of augmenting nutrient transport in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof.

19. (Withdrawn – currently amended) A method of regulating lipolysis in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof.

20. (Withdrawn – currently amended) A method of regulating blood flow in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof.

21. (Withdrawn – currently amended) A method of facilitating weight loss, appetite decrease, weight maintenance, treating obesity, treating diabetes, treating complications of diabetes including retinopathy, or treating cardiovascular disorders in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof.

22. (Withdrawn) A method according to claim 21, wherein excessive weight is a contributing factor to a disease or condition including hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis and cancers.

23. (Withdrawn) A method according to claim 22, wherein said facilitation of weight loss reduces the likelihood of such diseases or conditions or where said facilitation of weight loss comprises at least part of a treatment for such diseases or conditions.

24. (Withdrawn – currently amended) A method of antagonizing the effects of PYY(3-36) in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 3~~ any one of claims 8-12, or a pharmaceutically acceptable salt thereof, wherein said compound is a PYY antagonist.

25. (Withdrawn) A method according to claim 24, wherein said antagonist effects in said mammal comprise facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase.
26. (Withdrawn) A method according to claim 25, wherein said facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase is indicated in a mammal having a disease or disorder, or under going a treatment, accompanied by weight loss.
27. (Withdrawn) A method according to claim 26, wherein said diseases or disorders accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, wasting, cachexia, and wasting in frail elderly.
28. (Withdrawn) A method according to claim 26, wherein said treatment accompanied by weight loss comprises chemotherapy, radiation therapy, temporary or permanent immobilization, or dialysis.